Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Diphencyprone (DPCP)

Phase 1Small molecule

NNicholas Gulati

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Immune Checkpoint InhibitionRecruiting

Immune Checkpoint InhibitionPhase 1

Recruiting

Timeline

Expected Milestones

Q4 2030

Phase 1Recruiting

Immune Checkpoint Inhibition

NCT05481658

Clinical

Trials by Indication[1]

Immune Checkpoint Inhibition1 trial

Diphencyprone Plus Immune Checkpoint Inhibition in the Treatment of Cutaneous Metastases

Recruiting·NNicholas Gulati·Phase 1·NCT05481658·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Diphencyprone (DPCP). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Diphencyprone (DPCP) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Diphencyprone (DPCP). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Nicholas Gulati company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: NNicholas Gulati

Related News